AnaptysBio, Inc. (ANAB)
Market Cap | 654.01M |
Revenue (ttm) | 22.96M |
Net Income (ttm) | -163.30M |
Shares Out | 27.32M |
EPS (ttm) | -6.14 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 245,929 |
Open | 24.42 |
Previous Close | 24.61 |
Day's Range | 23.72 - 24.76 |
52-Week Range | 13.36 - 27.50 |
Beta | -0.32 |
Analysts | Buy |
Price Target | 46.38 (+93.73%) |
Earnings Date | Aug 5, 2024 |
About ANAB
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and I... [Read more]
Financial Performance
In 2023, AnaptysBio's revenue was $17.16 million, an increase of 66.78% compared to the previous year's $10.29 million. Losses were -$163.62 million, 27.1% more than in 2022.
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for ANAB stock is "Buy." The 12-month stock price forecast is $46.38, which is an increase of 93.73% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/g/7/press20-2422695.jpg)
Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update
SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported financial r...
![](https://cdn.snapi.dev/images/v1/o/i/press6-2422628.jpg)
Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)
SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced positive t...
![](https://cdn.snapi.dev/images/v1/1/t/press13-2422569.jpg)
Anaptys to Receive $50 Million in a Capped Non-Recourse Monetization from Amended Agreement with Sagard in Exchange for Additional Jemperli Royalties
SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced the execut...
![](https://cdn.snapi.dev/images/v1/p/r/press8-2388131.jpg)
Actym Therapeutics Appoints Thomas Smart as CEO
BERKELEY, Calif. , April 24, 2024 /PRNewswire/ -- Actym Therapeutics, pioneering a new drug modality to treat solid tumors, announced today the appointment of Thomas Smart as Chief Executive Officer.
![](https://cdn.snapi.dev/images/v1/o/c/press19-2318683.jpg)
Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
SAN DIEGO, March 11, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported operating...
![](https://cdn.snapi.dev/images/v1/v/b/conf15-2301203.jpg)
Anaptys to Present at TD Cowen's 44th Annual Health Care Conference and 2024 AAD Annual Meeting
SAN DIEGO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Dani...
![](https://cdn.snapi.dev/images/v1/b/i/conf10-2253107.jpg)
Anaptys to Present at Guggenheim's 6th Annual Biotechnology Conference
SAN DIEGO, Jan. 31, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Dani...
![](https://cdn.snapi.dev/images/v1/e/h/press10-2172926.jpg)
Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals
SAN DIEGO, Nov. 27, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced an exclus...
![](https://cdn.snapi.dev/images/v1/0/i/press9-2145281.jpg)
Anaptys Named a BioSpace 2024 Best Places to Work Winner
SAN DIEGO, Nov. 07, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that, for...
![](https://cdn.snapi.dev/images/v1/b/y/press9-2137631.jpg)
Anaptys Announces Third Quarter 2023 Financial Results and Provides Business Update
SAN DIEGO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported operating ...
![](https://cdn.snapi.dev/images/v1/n/u/conf15-2132992.jpg)
Anaptys Announces Participation in November Investor Conferences
SAN DIEGO, Nov. 01, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Dani...
![](https://cdn.snapi.dev/images/v1/v/d/conf14-2098801.jpg)
Anaptys to Present Phase 1 Data on ANB032, its BTLA Agonist Antibody, at the 32nd EADV Congress
SAN DIEGO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced two upcom...
![](https://cdn.snapi.dev/images/v1/w/z/mwqbx4ag7vienjlnkqyzcbnvsq-2094918.jpg)
AnaptysBio's skin disease drug meets main goal in late-stage study
AnaptysBio Inc said on Monday its experimental drug to treat a type of rare skin disease met the main goal in a late-stage study.
![](https://cdn.snapi.dev/images/v1/2/j/press17-2094861.jpg)
Anaptys to Provide Overview of Rosnilimab, a PD-1 Agonist, at Virtual R&D Event on Wednesday, Oct. 25
SAN DIEGO, Oct. 09, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced it will h...
![](https://cdn.snapi.dev/images/v1/u/b/press12-2094800.jpg)
Anaptys Announces Positive Top-Line Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)
SAN DIEGO, Oct. 09, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced positive ...
![](https://cdn.snapi.dev/images/v1/o/d/press12-2068152.jpg)
AnaptysBio Announces Appointment of John Orwin as Chairman of the Board of Directors
SAN DIEGO, Sept. 18, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced it has a...
![](https://cdn.snapi.dev/images/v1/s/r/conf5-2059573.jpg)
AnaptysBio to Present at the Stifel 2023 Immunology and Inflammation Virtual Summit
SAN DIEGO, Sept. 12, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Dan...
![](https://cdn.snapi.dev/images/v1/c/q/press13-2010565.jpg)
AnaptysBio Announces Second Quarter 2023 Financial Results and Provides Business Update
SAN DIEGO, Aug. 07, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported operating ...
![](https://cdn.snapi.dev/images/v1/i/5/press7-1997234.jpg)
AnaptysBio- and GSK-Partnered Immuno-Oncology Agent JEMPERLI (dostarlimab-gxly) plus Chemotherapy Approved in the U.S. for dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer
SAN DIEGO, July 31, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that GSK ...
![](https://cdn.snapi.dev/images/v1/n/f/conf2-1913055.jpg)
AnaptysBio Announces Participation in Upcoming Investor Conferences
SAN DIEGO, May 30, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Danie...
![](https://cdn.snapi.dev/images/v1/t/i/press2-1886317.jpg)
AnaptysBio Announces First Quarter 2023 Financial Results and Provides Pipeline Update
SAN DIEGO, May 11, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported operating r...
![](https://cdn.snapi.dev/images/v1/f/d/press17-1865588.jpg)
AnaptysBio Announces British Journal of Dermatology Publication of Imsidolimab (IL-36R) Previously Reported Phase 2 GALLOP Data in Generalized Pustular Psoriasis (GPP)
SAN DIEGO, May 02, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced the public...
![](https://cdn.snapi.dev/images/v1/j/n/press19-1829014.jpg)
AnaptysBio Announces Appointment of Rita Jain, M.D., to Board of Directors
SAN DIEGO, April 06, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced the appo...
![](https://cdn.snapi.dev/images/v1/x/u/press19-1814352.jpg)
AnaptysBio- and GSK-partnered immuno-oncology agent Jemperli (dostarlimab-gxly) plus chemotherapy demonstrates statistically significant and clinically meaningful improvement in progression-free survival for the treatment of primary advanced or recurrent endometrial cancer versus chemotherapy alone in Phase 3 RUBY trial
SAN DIEGO, March 27, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that GSK...
![](https://cdn.snapi.dev/images/v1/j/v/press14-1778000.jpg)
AnaptysBio Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
SAN DIEGO, March 01, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported operating...